Novo Nordisk CSO warns NASH market will develop slowly, urges all to 'moderate expectations'

28 November 2017

Mads Krogsgaard Thomsen, Novo Nordisk (NOV: N) employee for over a quarter of a century, says he has "been through all the miserable failures as well as the successes of the company, from products that are now off patent to those that don't yet have one."

Professor Thomsen, who calls himself "a bit of an old timer," joined the firm in 1991 as head of growth hormone research, and subsequently worked in diabetes as head of research before leading R&D for the whole company and becoming chief scientific officer at the turn of the millennium.

As 2017 draws to a close, The Pharma Letter caught up with him to discover highlights from the year that was, and a look ahead to the key events for Novo Nordisk next year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK